Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Integrated genomic analyses of ovarian carcinoma

Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works

Mutational landscape and significance across 12 major cancer types

Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

The repertoire of mutational signatures in human cancer

Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020) · Nature · doi:10.1038/s41586-020-1943-3 · Cited by 3,496 · see citing works

Ovarian Cancer

Rubin, M., & Stephen, C. D. (1993) · Cited by 3,161 · see citing works

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · see citing works

Liquid biopsies come of age: Towards implementation of circulating tumour DNA

Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538 · see citing works

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452 · see citing works

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

González-Martı́n, A., Pothuri, B., Vergote, I. B., Christensen, R. D., Graybill, W. A. S., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P. J., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,278 · see citing works

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · see citing works

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218 · see citing works

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,217 · see citing works

A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer

Bast, R. C., Klug, T. L., John, E. S., Jenison, E. L., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T. J., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135 · see citing works

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Ray-Coquard, I. L., Pautier, P., Pignata, S., Pérol, D., González-Martı́n, A., Berger, R., Fujiwara, K., Vergote, I. B., Colombo, N., Maenpaa, J. U., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,072 · see citing works

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Pujade-Lauraine, É., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A. M., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,856 · see citing works

Ovarian cancer

Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,853 · see citing works

cGAS surveillance of micronuclei links genome instability to innate immunity

Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · see citing works

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · see citing works

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C. A., Oaknin, A., Dean, A. P., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,699 · see citing works

Hallmarks of 'BRCAness' in sporadic cancers

Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,651 · see citing works

Playing the End Game: DNA Double-Strand Break Repair Pathway Choice

Chapman, J. R., Taylor, M. R. G., & Boulton, S. J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.029 · Cited by 1,629 · see citing works

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · see citing works

Mitotic progression following DNA damage enables pattern recognition within micronuclei

Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508 · see citing works

Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

Tothill, R. W., Tinker, A. V., George, J., Brown, R. E., Fox, S. B., Lade, S., Johnson, D., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,472 · see citing works

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Kehoe, S. T., Hook, J., Nankivell, M. G., Jayson, G. C., Kitchener, H. C., Lopes, T., Luesley, D. M., Perren, T. J., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414 · see citing works

Emerging landscape of oncogenic signatures across human cancers

Ciriello, G., Miller, M. L., Aksoy, B. A., Şenbabaoğlu, Y., Schultz, N. D., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,382 · see citing works

The Concept of Synthetic Lethality in the Context of Anticancer Therapy

Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,369 · see citing works

Staging classification for cancer of the ovary, fallopian tube, and peritoneum

Prat, J. (2013) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,366 · see citing works

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

Forshew, T., Murtaza, M., Parkinson, C., Gale, D. G., Tsui, D. W. Y., Kaper, F., Dawson, S., Piskorz, A., Jimenez‐Liñan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,298 · see citing works

BRCAness revisited

Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257 · see citing works

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

Jones, S., Wang, T., Shih, I., Mao, T., Nakayama, K., Roden, R. B. S., Glas, R., Slamon, D. J., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,218 · see citing works

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197 · see citing works

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196 · see citing works

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192 · see citing works

State-of-the-art strategies for targeting the DNA damage response in cancer

Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · see citing works

BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,179 · see citing works

Non-Invasive Analysis of Acquired Resistance to Cancer Therapy By Sequencing of Plasma Dna

(2014) · Annals of Oncology · doi:10.1093/annonc/mdu312.5 · Cited by 1,174 · see citing works

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · see citing works

Enhanced detection of circulating tumor DNA by fragment size analysis

Mouliere, F. C., Chandrananda, D., Piskorz, A., Moore, E. K., Morris, J., Ahlborn, L. B., Mair, R. J., Goranova, T., Marass, F., Heider, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat4921 · Cited by 1,071 · see citing works

The evolutionary history of 2,658 cancers

Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2020) · Nature · doi:10.1038/s41586-019-1907-7 · Cited by 1,057 · see citing works

Resistance to therapy caused by intragenic deletion in BRCA2

Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · see citing works

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70404-1 · Cited by 939 · see citing works

The Dualistic Model of Ovarian Carcinogenesis

Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 933 · see citing works

Replication fork stability confers chemoresistance in BRCA-deficient cells

Chaudhuri, A. R., Callén, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 917 · see citing works

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M. L., Okamoto, A., Moore, K. N., Ben-Baruch, N. E., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 915 · see citing works

The operational environment and rotational acceleration of asteroid (101955) Bennu from OSIRIS-REx observations

Hergenrother, C. W., Maleszewski, C., Nolan, M. C., Li, J., d’Aubigny, C. D., Shelly, F. C., Howell, E. S., Kareta, T., Izawa, M. R. M., Barucci, M. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09213-x · Cited by 902 · see citing works

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Oza, A. M., Cook, A. D., Pfisterer, J., Embleton-Thirsk, A., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 876 · see citing works

Mechanisms underlying mutational signatures in human cancers

Helleday, T., Eshtad, S., & Nik‐Zainal, S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3729 · Cited by 841 · see citing works

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

Markman, M. M., Rothman, R., Hakes, T. B., Reichman, B. S., Hoskins, W. J., Rubin, S. C., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 838 · see citing works

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 818 · see citing works

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 786 · see citing works

The “cancer immunogram”

Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748 · see citing works

PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743 · see citing works

Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · see citing works

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Yuan, M., Huang, L., Chen, J., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 678 · see citing works

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S. J., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 621 · see citing works

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

Shen, J., Zhao, W., Ju, Z., Wang, L., Peng, Y., Labrie, M., Yap, T. A., Mills, G. B., & Peng, G. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1003 · Cited by 599 · see citing works

Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

Norquist, B. M., Wurz, K., Pennil, C. C., Garcia, R. L., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577 · see citing works

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., Hendrickson, A. E. W., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30029-4 · Cited by 532 · see citing works

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Felder, M. A. R., Kapur, A., Bosquet, J. G., Horibata, S., Heintz, J. A., Albrecht, R. M., Fass, L., kaur, J., Hu, K. S., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 526 · see citing works

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

Jaspers, J. E., Kersbergen, A. J., Boon, U., Sol, W., van Deemter, L., Zander, S. A. L., Drost, R., Wientjens, E., Ji, J. J., Aly, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0049 · Cited by 515 · see citing works

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan, D. S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-jones, A., Norman, A., Kaye, S., & Gore, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 489 · see citing works

Mutational signatures: the patterns of somatic mutations hidden in cancer genomes

Alexandrov, L. B., & Stratton, M. R. (2014) · Current Opinion in Genetics &amp; Development · doi:10.1016/j.gde.2013.11.014 · Cited by 488 · see citing works

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 480 · see citing works

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Pettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M. R., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 454 · see citing works

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 449 · see citing works

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Lin, K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I. L., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 441 · see citing works

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Cruz, C., Castroviejo‐Bermejo, M., Gutiérrez‐Enríquez, S., Llop‐Guevara, A., Ibrahim, Y. H., Gris‐Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 437 · see citing works

Copy number signatures and mutational processes in ovarian carcinoma

Macintyre, G., Goranova, T., Silva, D. D., Ennis, D. P., Piskorz, A., Eldridge, M., Sie, D., Lewsley, L.-A., Hanif, A., Wilson, C. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0179-8 · Cited by 434 · see citing works

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

Zhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B. P., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 422 · see citing works

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 419 · see citing works

Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling

Bashashati, A., Ha, G., Tone, A. A., Ding, J., Prentice, L., Roth, A. J. L., Rosner, J., Shumansky, K., Kalloger, S. E., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 413 · see citing works

MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells

Lemacon, D. S., Jackson, J., Quinet, A., Brickner, J. R., Li, S., Yazinski, S. A., You, Z., Ira, G., Zou, L., Mosammaparast, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01180-5 · Cited by 410 · see citing works

Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis

Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A., Gale, D. G., Sayal, K., Murtaza, M., Baldwin, P., et al. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 403 · see citing works

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline

Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., Kohn, E. C., Levine, D. A., Liu, J. F., Lu, K. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02960 · Cited by 381 · see citing works

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Llobet, S. G., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 376 · see citing works

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents

Zoppoli, G. M., Regairaz, M., Leo, E., Reinhold, W. C., Varma, S., Ballestrero, A., Doroshow, J. H., & Pommier, Y. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205943109 · Cited by 369 · see citing works

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364 · see citing works

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer

Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Gierc, N. S., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 349 · see citing works

Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 346 · see citing works

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 326 · see citing works

DNA Damage and Cancer Immunotherapy: A STING in the Tale

Reisländer, T., Groelly, F. J., & Tarsounas, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.026 · Cited by 318 · see citing works

Detecting the mutational signature of homologous recombination deficiency in clinical samples

Gulhan, D., Lee, J. J.-K., Melloni, G. E. M., Cortés‐Ciriano, I., & Park, P. J. (2019) · Nature Genetics · doi:10.1038/s41588-019-0390-2 · Cited by 316 · see citing works

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316 · see citing works

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Vergote, I. B., Coens, C., Nankivell, M. G., Kristensen, G. B., Parmar, M., Ehlen, T., Jayson, G. C., Johnson, N. P., Swart, A. M., Verheijen, R. H. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30566-7 · Cited by 315 · see citing works

Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study

Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307 · see citing works

Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma

Böhm, S., Faruqi, A. Z., Said, I., Lockley, M., Brockbank, E. C., Jeyarajah, A., Fitzpatrick, A., Ennis, D. P., Dowe, T., Santos, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.5212 · Cited by 302 · see citing works

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Färkkilä, A., Gulhan, D., Casado, J., Jacobson, C. A., Nguyen, H. Q., Kochupurakkal, B. S., Maliga, Z., Yapp, C., Chen, Y., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 302 · see citing works

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Parkinson, C., Gale, D. G., Piskorz, A., Biggs, H., Hodgkin, C., Addley, H. C., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 299 · see citing works

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. G. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 298 · see citing works

Correction: Corrigendum: 14-3-3ζ regulates the mitochondrial respiratory reserve linked to platelet phosphatidylserine exposure and procoagulant function

Schoenwaelder, S. M., Darbousset, R., Cranmer, S. L., Ramshaw, H. S., Orive, S. L., Sturgeon, S. A., Yuan, Y., Yao, Y., Krycer, J. R., Woodcock, J. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms16125 · Cited by 293 · see citing works

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Penson, R. T., Villalobos-Valencia, R., Cibula, D., Colombo, N., Leath, C. A., Bidziński, M., Kim, J., Nam, J., Mądry, R., Hernández, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02745 · Cited by 291 · see citing works

Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma

Guan, B., Mao, T., Panuganti, P. K., Kuhn, E., Kurman, R. J., Maeda, D., Chen, E., Jeng, Y., Wang, T., & Shih, I. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318212782a · Cited by 287 · see citing works

SLFN11 Blocks Stressed Replication Forks Independently of ATR

Murai, J., Tang, S.-W., Leo, E., Baechler, S. A., Redon, C. E., Zhang, H., Al Abo, M., Rajapakse, V. N., Nakamura, E., Jenkins, L. M. M., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.012 · Cited by 275 · see citing works

The impact of replication stress on replication dynamics and DNA damage in vertebrate cells

Técher, H., Koundrioukoff, S., Nicolas, A. G., & Debatisse, M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.46 · Cited by 271 · see citing works

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomský, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 266 · see citing works

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Weigelt, B., Comino‐Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C. V., Cutts, R., Martelotto, L. G., Ng, C. K. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0544 · Cited by 266 · see citing works

Ovarian carcinoma pathology and genetics: recent advances

Gilks, C. B., & Prat, J. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.04.017 · Cited by 250 · see citing works

Replication stress: getting back on track

Berti, M., & Vindigni, A. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3163 · Cited by 249 · see citing works

Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy

Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O. M., Couturier, D., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 244 · see citing works

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Hodgson, D., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L. M., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233 · see citing works

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Morrison, J., Haldar, K., Kehoe, S. T., & Lawrie, T. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005343.pub3 · Cited by 232 · see citing works

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

Köbel, M., Rahimi, K., Rambau, P., Naugler, C. T., Page, C. L., Meunier, L., de Ladurantaye, M., Lee, S., Leung, S. C. Y., Goode, E. L., et al. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000274 · Cited by 221 · see citing works

Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer

Bolton, K., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S., Karlan, B., Lambrechts, D., Despierre, E., Barrowdale, D., McGuffog, L., et al. (2012) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2012.20 · Cited by 219 · see citing works

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219 · see citing works

Defective removal of ribonucleotides from DNA promotes systemic autoimmunity

Günther, C., Kind, B., Reijns, M. A. M., Berndt, N., Martínez‐Bueno, M., Wolf, C., Tüngler, V., Chara, O., Lee, Y. A., Hübner, N., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78001 · Cited by 218 · see citing works

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

ter Brugge, P., Kristel, P., van der Burg, E., Boon, U., de Maaker, M., Lips, E. H., Mulder, L., de Ruiter, J., Moutinho, C., Gevensleben, H., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw148 · Cited by 215 · see citing works

Evolution of platinum resistance in high-grade serous ovarian cancer

Cooke, S. L., & Brenton, J. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70123-1 · Cited by 213 · see citing works

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Clamp, A. R., James, E. C., McNeish, I. A., Dean, A. P., Kim, J., O’Donnell, D. M., Hook, J., Coyle, C., Blagden, S. P., Brenton, J. D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32259-7 · Cited by 210 · see citing works

A community-maintained standard library of population genetic models

Adrion, J. R., Cole, C. B., Dukler, N., Galloway, J., Gladstein, A. L., Gower, G., Kyriazis, C. C., Ragsdale, A. P., Tsambos, G., Baumdicker, F., et al. (2020) · eLife · doi:10.7554/elife.54967 · Cited by 206 · see citing works

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes

Hunter, S. M., Chenevix‐Trench, G., Anglesio, M. S., Ryland, G. L., Sharma, R. N., Chiew, Y.-E., Rowley, S. M., Doyle, M., Li, J., Gilks, C. B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5438 · Cited by 204 · see citing works

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1443 · Cited by 202 · see citing works

Obstetrics and Gynecology

Spitzer, R. F., & Thistle, P. (2017) · CRC Press eBooks · doi:10.1201/9781315155210-15 · Cited by 200 · see citing works

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200 · see citing works

Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer

Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 198 · see citing works

Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer

Christie, E. L., Pattnaik, S., Beach, J. A., Copeland, A., Rashoo, N., Fereday, S., Hendley, J., Alsop, K., Brady, S. W., Lamb, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09312-9 · Cited by 193 · see citing works

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Reisländer, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Vito, S. D., Wright, B., Lockstone, H. E., Biroccio, A., Harris, A. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11048-5 · Cited by 192 · see citing works

The molecular origin and taxonomy of mucinous ovarian carcinoma

Cheasley, D. A., Wakefield, M. J., Ryland, G. L., Allan, P. E., Alsop, K., Amarasinghe, K. C., Ananda, S. S., Anglesio, M. S., Au‐Yeung, G., Böhm, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11862-x · Cited by 190 · see citing works

An Immunohistochemical Comparison Between Low-Grade and High-Grade Ovarian Serous Carcinomas

O’Neill, C., Deavers, M. T., Malpica, A. L., Foster, H., & McCluggage, W. G. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000166367.68459.7d · Cited by 163 · see citing works

Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment

Naipal, K. A. T., Verkaik, N. S., Ameziane, N., van Deurzen, C. H. M., ter Brugge, P., Meijers, M., Sieuwerts, A. M., Martens, J. W. M., O’Connor, M. J., Vrieling, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0571 · Cited by 162 · see citing works

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Waks, A. G., Cohen, O., Kochupurakkal, B. S., Kim, D., Dunn, C. E., Buendia, J., Wander, S. A., Helvie, K. E., Lloyd, M. R., Marini, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.008 · Cited by 162 · see citing works

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety

Matulonis, U. A., Penson, R. T., Domchek, S. M., Kaufman, B., Shapira‐Frommer, R., Audeh, M. W., Kaye, S. B., Molife, L. R., Gelmon, K. A., Robertson, J. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw133 · Cited by 159 · see citing works

Clinicopathological characteristics of mucinous adenocarcinoma of the ovary

Shimada, M., Kigawa, J., Ohishi, Y., Yasuda, M., Suzuki, M., Hiura, M., Nishimura, R., Tabata, T., Sugiyama, T., & Kaku, T. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.02.010 · Cited by 159 · see citing works

The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study

Funston, G., Hamilton, W. T., Abel, G., Crosbie, E. J., Rous, B., & Walter, F. M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003295 · Cited by 152 · see citing works

Significantly Greater Expression of ER, PR, and ECAD in Advanced-Stage Low-Grade Ovarian Serous Carcinoma as Revealed by Immunohistochemical Analysis

Wong, K., Lu, K. H., Malpica, A. L., Bodurka, D. C., Shvartsman, H. S., Schmandt, R. E., Thornton, A., Deavers, M. T., Silva, E. G., & Gershenson, D. M. (2007) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31803025cd · Cited by 143 · see citing works

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations

Birkbak, N. J., Kochupurakkal, B. S., Izarzugaza, J. M. G., Eklund, A. C., Li, Y., Liu, J. F., Szállási, Z., Matulonis, U. A., Richardson, A. L., Iglehart, J. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080023 · Cited by 141 · see citing works

BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity

Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140 · see citing works

DNA damage and innate immunity: links and trade-offs

Chatzinikolaou, G., Karakasilioti, I., & Garinis, G. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.06.003 · Cited by 139 · see citing works

FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy

Ison, G., Howie, L. J., Amiri‐Kordestani, L., Zhang, L., Tang, S. W., Sridhara, R., Pierre, V., Charlab, R., Ramamoorthy, A., Song, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0042 · Cited by 137 · see citing works

DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs

Li, M., Kao, E., Malone, D., Gao, X., Wang, J. Y. J., & David, M. (2018) · Nature Structural &amp; Molecular Biology · doi:10.1038/s41594-018-0142-5 · Cited by 136 · see citing works

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Gasparri, M. L., Bardhi, E., Ruscito, I., Papadia, A., Farooqı, A. A., Marchetti, C., Bogani, G., Ceccacci, I., Mueller, M. D., & Panici, P. B. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-118907 · Cited by 136 · see citing works

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response

Kim, C., Wang, X.-D., & Yu, Y. (2020) · eLife · doi:10.7554/elife.60637 · Cited by 136 · see citing works

New roles for the major human 3′-5′ exonuclease TREX1 in human disease

Kavanagh, D., Spitzer, D., Kothari, P. H., Shaikh, A., Liszewski, M. K., Richards, A., & Atkinson, J. P. (2008) · Cell Cycle · doi:10.4161/cc.7.12.6162 · Cited by 132 · see citing works

Risk of Gynecologic Cancer According to the Type of Endometriosis

Saavalainen, L., Lassus, H. J., But, A., Tiitinen, A. E., Härkki, P., Gissler, M., Pukkala, ­., & Heikinheimo, O. (2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002624 · Cited by 132 · see citing works

Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275

Galsky, M. D., Saci, A., Szabó, P. M., Han, G. C., Grossfeld, G. D., Collette, S., Siefker-Radtke, A. O., Necchi, A., & Sharma, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4162 · Cited by 131 · see citing works

Integrated genomic analyses of ovarian carcinoma

The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works

The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches

Gerwing, M., Herrmann, K., Helfen, A., Schliemann, C., Berdel, W. E., Eisenblätter, M., & Wildgruber, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0169-5 · Cited by 127 · see citing works

Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer

Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 125 · see citing works

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy

Stronach, E. A., Paul, J., Timms, K. M., Hughes, E., Brown, K. L., Neff, C. D., Perry, M., Gutin, A., El-Bahrawy, M. A., Steel, J. H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0034 · Cited by 121 · see citing works

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Cohen, P. A., Powell, A., Böhm, S., Gilks, C. B., Stewart, C. J. R., Meniawy, T. M., Bulsara, M. K., Avril, S., Brockbank, E. C., Bosse, T., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.04.679 · Cited by 120 · see citing works

Extreme rainfall events alter the trophic structure in bromeliad tanks across the Neotropics

Romero, G. Q., Marino, N. A. C., MacDonald, A. A. M., Céréghino, R., Trzcinski, M. K., Acosta-Mercado, D., Leroy, C., Corbara, B., Farjalla, V. F., Barberis, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17036-4 · Cited by 112 · see citing works

Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

Willers, H., Taghian, A. G., Luo, C., Treszezamsky, A. D., Sgroi, D. C., & Powell, S. N. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0149 · Cited by 110 · see citing works

CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

Walton, J. B., Farquharson, M., Mason, S. M., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D. J., Matzuk, M. M., Kim, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17119-1 · Cited by 110 · see citing works

Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers

Zhu, B., Song, N., Shen, R., Arora, A., Machiela, M. J., Song, L., Landi, M. T., Ghosh, D., Chatterjee, N., Baladandayuthapani, V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17031-8 · Cited by 109 · see citing works

RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance

Wang, Y., Krais, J. J., Bernhardy, A. J., Nicolas, É., Cai, K. Q., Harrell, M. I., Kim, H. H., George, E. M., Swisher, E. M., Simpkins, F. A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87033 · Cited by 107 · see citing works

Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

Poveda, A. M., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.6002 · Cited by 107 · see citing works

Endometrioid epithelial ovarian cancer

Storey, D. J., Rush, R., Stewart, M., Rye, T., Al-Nafussi, A., Williams, A. R. W., Smyth, J. F., & Gabra, H. (2008) · Cancer · doi:10.1002/cncr.23438 · Cited by 102 · see citing works

Low-grade serous carcinoma of the ovary or peritoneum

Gershenson, D. M. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw085 · Cited by 101 · see citing works

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications

Duska, L., & Kohn, E. C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx445 · Cited by 101 · see citing works

Low Grade Serous Ovarian Carcinoma: From the molecular characterization to the best therapeutic strategy

Pepa, C. D., Tonini, G., Santini, D., Losito, S., Pisano, C., Napoli, M. D., Cecere, S. C., Gargiulo, P., & Pignata, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.003 · Cited by 97 · see citing works

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

Safra, T., Borgato, L., Nicoletto, M. O., Rolnitzky, L. M., Pelles-Avraham, S., Geva, R., Donach, M. E., Curtin, J. P., Novetsky, A. P., Grenader, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0272 · Cited by 94 · see citing works

BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study

Petrillo, M., Marchetti, C., Leo, R. D., Musella, A., Capoluongo, E., Paris, I., Panici, P. B., Scambia, G., & Fagotti, A. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.05.036 · Cited by 89 · see citing works

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition

Lheureux, S., Bruce, J. P., Burnier, J. V., Karakasis, K., Shaw, P. A., Clarke, B. A., Yang, S. Y. C., Quevedo, R., Li, T., Dowar, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3677 · Cited by 88 · see citing works

New approaches for targeting platinum-resistant ovarian cancer

McMullen, M., Madariaga, A., & Lheureux, S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.013 · Cited by 88 · see citing works

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

Crawford, S. M., & Peace, J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdi012 · Cited by 87 · see citing works

The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life

Grandi, G., Toss, A., Cortesi, L., Botticelli, L., Volpe, A., & Cagnacci, A. (2015) · BioMed Research International · doi:10.1155/2015/751571 · Cited by 85 · see citing works

Ultrasound‐guided tru‐cut biopsy of abdominal and pelvic tumors in gynecology

Zikán, M., Fischerová, D., Pinkavova, I., Dundr, P., & Cibula, D. (2010) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.8803 · Cited by 80 · see citing works

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma

AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.328 · Cited by 73 · see citing works

Preventing Weight Gain in Women in Rural Communities: A Cluster Randomised Controlled Trial

Lombard, C. B., Harrison, C. L., Kozica, S. L., Zoungas, S., Ranasinha, S., & Teede, H. J. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1001941 · Cited by 71 · see citing works

Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary

Fadare, O., & Parkash, V. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2019.01.009 · Cited by 65 · see citing works

Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Morgan, R. D., McNeish, I. A., Cook, A. D., James, E. C., Lord, R., Dark, G. G., Glasspool, R. M., Krell, J., Parkinson, C., Poole, C. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30591-x · Cited by 65 · see citing works

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Coleridge, S. L., Bryant, A., Lyons, T. J., Goodall, R. J., Kehoe, S. T., & Morrison, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005343.pub4 · Cited by 64 · see citing works

New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study

Plaskocinska, I., Shipman, H., Drummond, J., Thompson, E., Buchanan, V., Newcombe, B., Hodgkin, C., Barter, E., Ridley, P., Ng, R., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103902 · Cited by 62 · see citing works

Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?

Griffin, N., Grant, L. A., Freeman, S. J., Jimenez‐Liñan, M., Berman, L., Earl, H. M., Ahmed, A. A., Crawford, R., Brenton, J. D., & Sala, E. (2008) · European Radiology · doi:10.1007/s00330-008-1121-8 · Cited by 60 · see citing works

Efficient Deletion of Normal Brca2-Deficient Intestinal Epithelium by Poly(ADP-Ribose) Polymerase Inhibition Models Potential Prophylactic Therapy

Hay, T., Jenkins, H., Sansom, O. J., Martin, N. M. B., Smith, G. C. M., & Clarke, A. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1186 · Cited by 59 · see citing works

Erratum: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer

Koti, M., Siu, A., Clément, I., Bidarimath, M., Turashvili, G., Edwards, A. K., Rahimi, K., Mes‐Masson, A., & Squire, J. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.459 · Cited by 59 · see citing works

The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study

Fader, A. N., Java, J., Krivak, T. C., Bristow, R. E., Tergas, A. I., Bookman, M. A., Armstrong, D. K., Tanner, E. J., & Gershenson, D. M. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.016 · Cited by 58 · see citing works

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer

Koti, M., Siu, A., Clément, I., Bidarimath, M., Turashvili, G., Edwards, A., Rahimi, K., Masson, A.-M. M., & Squire, J. A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.81 · Cited by 57 · see citing works

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells

Ji, J. J., Kinders, R. J., Zhang, Y., Rubinstein, L., Kummar, S., Parchment, R. E., Tomaszewski, J. E., & Doroshow, J. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026152 · Cited by 54 · see citing works

Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma

Chan, A. M. Y., Enwere, E. K., McIntyre, J. B., Wilson, H., Nwaroh, C., Wiebe, N. J. P., Ou, Y., Liu, S., Wiedemeyer, K., Rambau, P., et al. (2020) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.168 · Cited by 53 · see citing works

Detection of ctDNA from Dried Blood Spots after DNA Size Selection

Heider, K., Wan, J. C. M., Hall, J. A. M., Belic, J., Boyle, S. E., Hudecova, I., Gale, D. G., Cooper, W. N., Corrie, P. G., Brenton, J. D., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa050 · Cited by 52 · see citing works

Distinct Patterns of Structural and Numerical Chromosomal Instability Characterize Sporadic Ovarian Cancer

Bayani, J., Paděrová, J., Murphy, J., Rosen, B. P., Zieleńska, M., & Squire, J. A. (2008) · Neoplasia · doi:10.1593/neo.08584 · Cited by 50 · see citing works

Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors

Fischerová, D., Cibula, D., Dundr, P., Zikán, M., Calda, P., Freitag, P., & Sláma, J. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01015.x · Cited by 49 · see citing works

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing

Mezzadra, R., de Bruijn, M. J. W., Jae, L. T., Gomez, R., Duursma, A. M., Scheeren, F. A., Brummelkamp, T. R., & Schumacher, T. N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212053 · Cited by 45 · see citing works

Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer

Oikkonen, J., Zhang, K., Salminen, L., Schulman, I., Lavikka, K., Andersson, N., Ojanperä, E., Hietanen, S., Grénman, S., Lehtonen, R., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00343 · Cited by 45 · see citing works

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Ewing, A., Meynert, A. M., Churchman, M., Grimes, G. R., Hollis, R. L., Herrington, C. S., Rye, T., Bartos, C., Croy, I., Ferguson, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4068 · Cited by 40 · see citing works

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial

Lindemann, K. Y., Kristensen, G. B., Mirza, M. R., Davies, L. C., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M. J., Raspagliesi, F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw238 · Cited by 40 · see citing works

Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing

Iwahashi, N., Sakai, K., Noguchi, T., Yahata, T., Matsukawa, H., Toujima, S., Nishio, K., & Ino, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-47030-w · Cited by 38 · see citing works

Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer

Kubelac, P. M., Genestie, C., Auguste, A., Mesnage, S. J. L., Formal, A. L., Pautier, P., Gouy, S., Morice, P., Bentivegna, E., Maulard, A., et al. (2020) · Cancers · doi:10.3390/cancers12030707 · Cited by 36 · see citing works

Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States

Penn, C. A., Wong, M. S., & Walsh, C. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.28620 · Cited by 36 · see citing works

Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.

Telli, M. L., Metzger, O., Timms, K. M., Evans, B. A., Vogel, D., Wei, H., Jones, J. T., WENSTRUP, R. J., McKee, M. D., Sullivan, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.519 · Cited by 35 · see citing works

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

Hong, R., Ma, F., Zhang, W., Yu, X., Li, Q., Luo, Y., Zhu, C., Jiang, W. B., & Xu, B. (2016) · BMC Cancer · doi:10.1186/s12885-016-2754-7 · Cited by 33 · see citing works

Up‐regulation of the interferon‐related genes in BRCA2 knockout epithelial cells

Xu, H., Xian, J., Viré, E. A., McKinney, S. E., Wei, V., Wong, J. W. H., Tong, R., Kouzarides, T., Caldas, C., & Aparicio, S. A. J. R. (2014) · The Journal of Pathology · doi:10.1002/path.4404 · Cited by 33 · see citing works

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

Coleman, R. L., Swisher, E. M., Oza, A. M., Scott, C. L., Giordano, H., Lin, K., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Kristeleit, R. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.5540 · Cited by 33 · see citing works

Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma

Montfort, A., Barker-Clarke, R. J., Piskorz, A., Supernat, A. M., Moore, L., Al-Khalidi, S., Böhm, S., Pharoah, P. D. P., McDermott, J. R., Balkwill, F. R., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0822-x · Cited by 31 · see citing works

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers

Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30 · see citing works

Supporting Those Who Go to Fight Ebola

Mello, M. M., Merritt, M. W., & Halpern, S. D. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001781 · Cited by 23 · see citing works

Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients

Pedersen, B. S., Konstantinopoulos, P. A., Spillman, M. A., & De, S. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22075 · Cited by 21 · see citing works

Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP‑Seq in neoadjuvant chemotherapy‑treated advanced ovarian cancer

Noguchi, T., Sakai, K., Iwahashi, N., Matsuda, K., Matsukawa, H., Yahata, T., Toujima, S., Nishio, K., & Ino, K. (2020) · Oncology Letters · doi:10.3892/ol.2020.11356 · Cited by 21 · see citing works

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

Hollis, R. L., Meynert, A. M., Churchman, M., Rye, T., Mackean, M., Nussey, F., Arends, M. J., Sims, A. H., Semple, C. A. M., Herrington, C. S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-017-3981-2 · Cited by 17 · see citing works

Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments

Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139 · see citing works

The Evolution of Ovarian Carcinoma Subclassification

Köbel, M., & Kang, E. Y. (2022) · Cancers · doi:10.3390/cancers14020416 · Cited by 128 · see citing works

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44 · see citing works

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., et al. (2022) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-022-02265-w · Cited by 32 · see citing works

Artificial intelligence in ovarian cancer drug resistance advanced 3PM approach: subtype classification and prognostic modeling

Zhang, C., Yang, J., Chen, S., Sun, L., Li, K., Lai, G., Peng, B., Zhong, X., & Xie, B. (2024) · The EPMA Journal · doi:10.1007/s13167-024-00374-4 · Cited by 33 · see citing works

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy

Kulkarni, S., Seneviratne, N., Tosun, Ç., & Madhusudan, S. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103830 · Cited by 26 · see citing works

Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis

Wang, Q., Chang, Z., Liu, X., Wang, Y. X., Feng, C., Ping, Y., & Feng, X. (2024) · Journal of Medical Internet Research · doi:10.2196/48527 · Cited by 21 · see citing works

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer

Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 15 · see citing works

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer

Yordanova, M., Hubert, A., & Hassan, S. N. (2021) · Pharmaceuticals · doi:10.3390/ph14121270 · Cited by 14 · see citing works

Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors

Funingana, I.-G., Bedia, J. S., Huang, Y.-W., Delgado‐González, A., Donoso, K., Gonzalez, V. D., Brenton, J. D., Ashworth, A., & Fantl, W. J. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-022-00979-9 · Cited by 14 · see citing works

Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis

Su, H., Jin, Y., Tao, C., Yang, H., Yang, E., Zhang, W., & Feng, F. (2023) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2023.34.e48 · Cited by 13 · see citing works

Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes

Bairi, K. E., Singh, S., & Page, C. L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.002 · Cited by 7 · see citing works

Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study

Delgado-Ortet, M., Reinius, M., McCague, C., Bura, V., Woitek, R., Rundo, L., Gill, A. B., Gehrung, M., Ursprung, S., Bolton, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1085874 · Cited by 6 · see citing works

PARP inhibitor combined with platinum activates the cGAS-STING pathway to enhance anti-PD-L1 immunotherapy in lung adenocarcinoma

Feng, Y., Han, Z., Liu, X., Yao, S., Li, Y., Han, Y., & Xia, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116325 · Cited by 3 · see citing works

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients

Delgado-Ortet, M., Bura, V., Funingana, I.-G., Hulse, D., Rundo, L., Brenton, J. D., Sala, E., & Sánchez, L. E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546324 · Cited by 2 · see citing works

Patient-derived organoids as a model to study tubo-ovarian carcinoma: a pathologist’s perspective

Alves‐Vale, C., Galvão, B., Silvestre, A. R., Pereira, J. S., Bei, L., Fernandes, J. P., Borralho, P., Carmo‐Fonseca, M., & Custódio, N. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01766-4 · Cited by 2 · see citing works

Coordinated protein modules define DNA damage responses to carboplatin at single-cell resolution in human ovarian carcinoma models

Bedia, J. S., Delgado‐González, A., Huang, Y.-W., Gonzalez, V. D., Funingana, I.-G., Rahil, Z., Mike, A., Lowber, A. J., Vias, M., Ashworth, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102295 · Cited by 2 · see citing works

Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer

Nakayama, J., McGaughey, M., Pindzola, G., Miller, E. M., Krivak, T. C., Morse, C. B., Crafton, S., Wield, A. M., Toole, J., & Summerscales, T. Z. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.11.021 · Cited by 1 · see citing works

Pharmacodynamic model of PARP1 inhibition and global sensitivity analyses can lead to cancer biomarker discoveryPreprint

Mertins, S. D., Isenberg, N. M., Reyes, K. G., Yoon, B.-J., Urban, N. M., Jogalekar, M. P., Diolaiti, M. E., Weil, M. R., & Stahlberg, E. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.08.527527 · Cited by 1 · see citing works

Promoting equitable genetic testing in ovarian cancer: the demonstration of improvement for molecular ovarian cancer testing (DEMO) project

Leung, E. Y. L., Funingana, I.-G., Bird, L., Alcaraz, M., Evans, A., Considine, A., Freeman, S. J., Jimenez‐Liñan, M., Spencer, C., Phanasan, K., et al. (2025) · BMJ Open Quality · doi:10.1136/bmjoq-2023-002720 · Cited by 1 · see citing works

The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma

Kahraman, S., & Şendur, M. A. N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_85

Role of AI in molecular cancer pharmacology

Chawla, G., Gupta, O., & Pradhan, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-31592-3.00017-0

Habitat Radiomics Based on Diffusion-weighted MRI for Predicting PARP Inhibitor Resistance in Advanced High-grade Serous Ovarian Cancer

Lin, Z., Chen, X., Yang, J., Chai, D., Li, R., Zhang, L., Lu, J., Zhu, P., Wang, L., Zhang, Z., et al. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.04.011

A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients

Phillips-Chavez, C., Watson, M., Coward, J. I. G., & Schloss, J. M. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02874-4 · Cited by 7 · see citing works

Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas

Page, C. L., Chung, J. W., Rahimi, K., Köbel, M., Provencher, D. M., & Mes‐Masson, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666191016143836 · Cited by 9 · see citing works

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer

Philips, T. J., Erickson, B. K., & Thomas, S. N. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1503107 · Cited by 3 · see citing works

1P Comprehensive assessment of gene mutations revealed overlapping responses for PARPi and chemotherapy in ovarian cancer cells

Tozzi, A., Coelho, R., Disler, M., Lombardo, F. C., Fedier, A., López, M. N., Freuler, F., Jacob, F., & Heinzelmann-Schwarz, V. A. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.019

DNA Repair–Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside

Díaz-Padilla, I., & Poveda, A. M. (2010) · Clinical Ovarian Cancer · doi:10.3816/coc.2010.n.005 · Cited by 6 · see citing works